Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of 68Ga-FAPi-46 in Interstitial Lung Disease
NCT05365802Phase 1Active, not recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Nov 2021
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga FAPI-46 in interstitial lung disease (ILD), sponsored by University of California, Los Angeles. Primary endpoint: Biodistribution of gallium Ga 68 FAPi-46 at 60 minutes. Started Nov 2021; status: active, not recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05365802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365802.